
Explore our latest Alzheimer’s disease research and educational resources at our #CTAD26 virtual booth, including care partner resources, disease education materials, expert videos and our neuroscience pipeline: bit.ly/4j5piu9

Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below:

Explore our latest Alzheimer’s disease research and educational resources at our #CTAD26 virtual booth, including care partner resources, disease education materials, expert videos and our neuroscience pipeline: bit.ly/4j5piu9

Don’t miss our latest Alzheimer’s disease research at #CTAD26. Learn more about the data we’re sharing and explore our key findings: bit.ly/4evIAHJ #OneBMS

Lung cancer remains the leading cause of cancer deaths worldwide, and many cases are diagnosed at advanced stages. During #LungCancerAwarenessMonth, see how we’re advancing science and working across the lung cancer community to change that: bit.ly/4jQPHhp #OneBMS

Join us at #ACR26 as we present the latest data from a Phase 1 study exploring CAR T cell therapy in severe refractory systemic lupus erythematosus.

Tomorrow at #ACR26, join us as we share research evaluating cardiovascular risk–associated measures in psoriatic arthritis and long-term multidomain clinical responses in systemic lupus erythematosus.

At #ACR26, we’re presenting our latest research on emerging CAR T therapy approaches in autoimmune diseases like systemic lupus erythematosus and beyond.

We're researching the CCR8 immune pathway and its role within the tumor microenvironment as part of our work to advance innovative immunotherapy approaches for solid tumors. Explore the science behind this research: bit.ly/4kG2iUO #SITC26 #OneBMS

Join us tomorrow at #ACR26 as we share real-world research exploring the current treatment landscape and societal burden of systemic lupus erythematosus.

At #ScientificSessions26, we're presenting 5-year cardiac magnetic resonance results examining long-term changes in cardiac structure in adults with obstructive hypertrophic cardiomyopathy (oHCM). Learn more: bit.ly/3WqGLpi

Join us at #ACR26 for multiple lightning talk sessions showcasing our latest science, underscoring unmet needs and highlighting the potential of our approach to transform care for patients.

During #ScientificSessions26, we’ll share the latest real-world data in adults with obstructive hypertrophic cardiomyopathy (oHCM), including effectiveness across genetic status and long-term Real-World outcomes. bit.ly/48yyOkz

Our latest research explores changes in proteomic cardiovascular risk scores among adults with obstructive hypertrophic cardiomyopathy (oHCM). Learn more at #ScientificSessions26: bit.ly/4jTs4oq

We’ll present new long-term results from the Phase 3 trial in pediatric patients with obstructive hypertrophic cardiomyopathy (oHCM) tomorrow at #HCMSCHICAGO. Learn more: bit.ly/4Ae3GT9

Join us at the GSA 2026 Annual Scientific Meeting as Dr. Pierre N. Tariot explores earlier recognition of psychosis and agitation in Alzheimer’s disease and identifies key barriers to their recognition with a patient-journey lens.

Our precision-focused approach to cancer research combines molecular and clinical expertise with insights from causal human biology to help guide scientific discovery. Learn more about our approach to cancer research: bit.ly/47ZQ0zr #ESMO26 #OneBMS

MTAP deletion is a genomic alteration found across multiple tumor types. Explore the biology and evolving unmet need in this patient population: bit.ly/4dXxXND #ESMO26